Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 6Withdrawn 4Terminated 3Active not recruiting 2Unknown 1Recruiting 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 3NET 1

Conditions

Breast Neoplasms 370Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 142Colorectal Neoplasms 139Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 123Lymphoma 115Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 89Head and Neck Neoplasms 89Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 62Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

telotristat ethyl 3lanreotide 1Panitumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Serotonin Syndrome × Clear all
NCT04713202 2023-02-10

NET-PACS

Big Ten Cancer Research Consortium

Phase 2 Withdrawn
EndocrineNET

Diarrhea, Neuroendocrine Tumors, Serotonin Syndrome

NCT04776876 2021-09-29

Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome

M.D. Anderson Cancer Center

Phase 2 Withdrawn

Serotonin Syndrome

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn
Endocrine

Carcinoid Heart Disease, Serotonin Syndrome

NCT01172717 2013-07-26

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Boston Medical Center

Phase 2 Withdrawn
Endocrine

Carcinoid Tumor, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡